WASHINGTON (AP) — Gilead Science Inc.'s earnings tumbled 17 percent in first quarter as steeper discounts and rebates on its blockbuster hepatitis C drugs cut into sales.
By MATTHEW PERRONE, St. Louis Post-Dispatch: Business
Thu, 04/28/2016 - 2:22pm